Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 3:13 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 3,910 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Prostatic Cancer Clear all
Recruiting Phase 2 Interventional

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy

NCT03821246
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer, Localized Prostate Cancer
Interventions
Atezolizumab, Tocilizumab, Etrumadenant
Drug
Lead sponsor
David Oh
Other
Eligibility
18 Years and older · Male only
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
2
States / cities
San Francisco, California • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 23, 2026, 3:13 PM EDT
Completed Not applicable Interventional Results available

Massage Therapy in Treating the Symptoms of Patients With Locally Advanced or Metastatic Cancer

NCT00253708
View directory record Official record
Conditions
Cancer
Interventions
management of therapy complications, massage therapy, pain therapy, psychosocial assessment and care, quality-of-life assessment
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2017 · Synced Oct 23, 2026, 3:13 PM EDT
Active, not recruiting Phase 2 Interventional

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

NCT03471650
View directory record Official record
Conditions
Prostate Cancer
Interventions
18F-DCFPyL Injection
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 23, 2026, 3:13 PM EDT
Completed Not applicable Interventional

Oral Cryotherapy to Decrease Taste Changes in Prostate Cancer Patients Receiving Taxane Chemotherapy

NCT07218718
View directory record Official record
Conditions
Prostate Carcinoma
Interventions
Best Practice, Oral Cryotherapy, Survey Administration
Other · Procedure
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 3:13 PM EDT
Terminated Phase 2 Interventional Results available

68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer

NCT04716725
View directory record Official record
Conditions
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Interventions
68Ga-PSMA-11, Positron Emission Tomography (PET)
Drug · Procedure
Lead sponsor
Thomas Hope
Other
Eligibility
18 Years and older · Male only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 15, 2026 · Synced Oct 23, 2026, 3:13 PM EDT
Completed Not applicable Interventional Results available

Proton Therapy for Low and Intermediate Risk Prostate Cancer

NCT00693238
View directory record Official record
Conditions
Prostate Cancer
Interventions
Low Risk Proton Radiation, Intermediate Risk Proton Radiation
Radiation
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older · Male only
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 23, 2026, 3:13 PM EDT
Completed Phase 2 Interventional Results available

Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence

NCT03396874
View directory record Official record
Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer Metastatic, Prostate Cancer Recurrent
Interventions
68Ga-PSMA
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Male only
Enrollment
1,435 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 3, 2023 · Synced Oct 23, 2026, 3:13 PM EDT
Completed Phase 2 Interventional Results available

Trial of NanoPac® Focal Therapy in Subjects With Prostate Cancer

NCT03077659
View directory record Official record
Conditions
Adenocarcinoma of the Prostate
Interventions
NanoPac®
Drug
Lead sponsor
NanOlogy, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2019 · Synced Oct 23, 2026, 3:13 PM EDT
Completed Phase 2 Interventional Results available

Neoadjuvant Bevacizumab Plus Docetaxel in High Risk Patients With Prostate Cancer Undergoing Radical Prostatectomy

NCT00321646
View directory record Official record
Conditions
Prostate Cancer, Adenocarcinoma of the Prostate
Interventions
Bevacizumab, Docetaxel
Drug
Lead sponsor
Mary-Ellen Taplin, MD
Other
Eligibility
18 Years and older · Male only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
Boston, Massachusetts • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Oct 23, 2026, 3:13 PM EDT
Completed No phase listed Observational

Influence of Psychosocial Distress and Lifetime Trauma Exposure on Traumatic Stress Among Oncology Patients on Clinical Trials

NCT02948413
View directory record Official record
Conditions
Lymphoma, Mesothelioma, Prostate Cancer, Leukemia
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Oct 23, 2026, 3:13 PM EDT
Terminated Phase 2 Interventional Results available

Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases

NCT00634582
View directory record Official record
Conditions
Metastatic Cancer, Prostate Cancer
Interventions
paricalcitol, immunoenzyme technique, laboratory biomarker analysis, dual x-ray absorptometry, quality-of-life assessment
Drug · Other · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years · Male only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 23, 2026, 3:13 PM EDT
Completed Phase 1 Interventional Results available

Trial of ARV-110 and Abiraterone in Participants With Metastatic Prostate Cancer

NCT05177042
View directory record Official record
Conditions
Prostate Cancer Metastatic
Interventions
Bavdegalutamide, Abiraterone
Drug
Lead sponsor
Arvinas Androgen Receptor, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
Santa Monica, California • New Haven, Connecticut • Fort Myers, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Oct 23, 2026, 3:13 PM EDT
Recruiting Not applicable Interventional

Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies

NCT06907446
View directory record Official record
Conditions
Prostate Cancer
Interventions
Comparison of Biopsy Needle Types for Prostate Biopsy
Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older · Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 23, 2026, 3:13 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Detection of Clinically Significant Prostate Cancer Using Transperineal Targeted Biopsy Compared to Standard Transrectal Biopsy

NCT03044197
View directory record Official record
Conditions
Prostate Cancer, Magnetic Resonance Imaging, Target Lesion, Fusion Biopsy, Clinically Significant Prostate Cancer, Transperineal
Interventions
MRI/ultrasound transperineal prostate biopsy, transrectal ultrasound-guided prostate biopsy
Device
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 5, 2019 · Synced Oct 23, 2026, 3:13 PM EDT
Completed Phase 1Phase 2 Interventional

Dose-Escalation Study of TH-302 in Combination With A) Gemcitabine or B) Docetaxel or C) Pemetrexed to Treat Advanced Solid Tumors

NCT00743379
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Prostate Cancer, Pancreatic Cancer
Interventions
TH-302
Drug
Lead sponsor
Threshold Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
11
States / cities
Scottsdale, Arizona • Indianapolis, Indiana • Shreveport, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated May 7, 2015 · Synced Oct 23, 2026, 3:13 PM EDT
Terminated Phase 2 Interventional Results available

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

NCT05177770
View directory record Official record
Conditions
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer
Interventions
SRF617, etrumadenant, zimberelimab
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
7
States / cities
Miami, Florida • Ann Arbor, Michigan • Las Vegas, Nevada + 4 more
Source: ClinicalTrials.gov public record
Updated May 8, 2025 · Synced Oct 23, 2026, 3:13 PM EDT
Withdrawn Phase 2 Interventional

Clinical Trial Comparing 3-D RT vs. IMRT in Post- Prostatectomy Prostate Cancer Patients

NCT02678520
View directory record Official record
Conditions
Prostate Cancer
Interventions
3-D Conformal Radiation Therapy, Intensity Modulated Radiation Therapy, Casodex, Zoladex , Lupron
Radiation · Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Fairway, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 23, 2026, 3:13 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging to Evaluate Prostate Cancer

NCT00182624
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Male only
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 23, 2026, 3:13 PM EDT
Completed Phase 1Phase 2 Interventional

Phase I/IIA Study of PET Imaging With 89Zr-Df-IAB2M in Metastatic Prostate Cancer

NCT01923727
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
[89Zr]Df-IAB2M
Biological
Lead sponsor
ImaginAb, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 13, 2020 · Synced Oct 23, 2026, 3:13 PM EDT
Recruiting Phase 2 Interventional

Trial Targeting Gut Bacterial Androgen Production to Reverse Therapeutic Resistance to Abiraterone in Patients With Metastatic Prostate Cancer

NCT06616597
View directory record Official record
Conditions
Prostate Cancer (Adenocarcinoma), Metastatic Prostate Cancer
Interventions
Abiraterone acetate, Dexamethasone, Metronidazole
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older · Male only
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 23, 2026, 3:13 PM EDT
Withdrawn Phase 2 Interventional

A Phase II Neoadjuvant Study of Enzalutamide, Abiraterone Acetate, Dutasteride and Degarelix in Men With Localized Prostate Cancer Pre-prostatectomy

NCT02159690
View directory record Official record
Conditions
Prostate Cancer, Localized Prostate Cancer
Interventions
Enzalutamide, Abiraterone acetate, Prednisone, Dutasteride, Degarelix
Drug
Lead sponsor
Kenneth Pienta, MD
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 26, 2015 · Synced Oct 23, 2026, 3:13 PM EDT
Enrolling by invitation No phase listed Observational

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

NCT05160480
View directory record Official record
Conditions
Prostate Cancer, Breast Cancer, Neuroendocrine Tumors
Interventions
Total-body PET imaging
Diagnostic Test
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 23, 2026, 3:13 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

ExoDx Prostate Evaluation in Prior Negative Prostate Biopsy Setting

NCT04357717
View directory record Official record
Conditions
Prostate Cancer
Interventions
ExoDx Prostate
Diagnostic Test
Lead sponsor
Exosome Diagnostics, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Baltimore, Maryland • Voorhees Township, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 23, 2026, 3:13 PM EDT
Recruiting No phase listed Observational

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT03452774
View directory record Official record
Conditions
Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes
Interventions
Clinical Trial Matching
Other
Lead sponsor
Massive Bio, Inc.
Industry
Eligibility
Not listed
Enrollment
50,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2040
U.S. locations
67
States / cities
Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 23, 2026, 3:13 PM EDT